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To the Editor,
We would like to thank Drs. Ece Salihoglu and Ziya
Salihoglu for their interest in our article.2
While not directly addressed in the paper, the
CURE clinical study data used in this paper considers
patient gas concentration alongside both ventilator
pressure and volume. The four CURE pilot trial
patients had FiO2 set to 40, 40, 55 and 65 with PaO2
measurements of 71, 84, 60 and 101 mmHg, respec-
tively. The McREM trial data used for validation did
not provide specific oxygenation results.3 However,
each patient’s initial P/F ratio is provided in Table 1 of
the paper, and indicates FiO2 varied in typical ranges.
3
The model presented in our paper was designed for
use in an upcoming clinical trial that aims to optimise
mechanical ventilation care.1,4 The trial uses two steps
to optimise oxygenation. Step 1 optimises alveolar
recruitment by titrating PEEP to the point of minimum
elastance. The model thus safely maximises oxygena-
tion via mechanics without adjusting FiO2. Step 2 uses
this foundation to titrate FiO2 to achieve patient SpO2
levels within 92-95%. This process minimises the risk
of excessively high oxygen levels, so the broad range of
patients with respiratory failure can be optimally
treated dependent on their specific condition and
response to ventilation.
Thank you again for your time and interest.
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